Stay updated with breaking news from Michael Klichinsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility,...
The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.
Carisma Therapeutics Inc. will present findings at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the Company's lead product candidate, CT-0508, a human epidermal growth factor...
Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 New translational analyses combining group 1 & group 2 continue to support...
PHILADELPHIA, Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced...